According to the results of the PPI network and KEGG pathway enrichment analyses, specific targets, including VEGFA, Bax, Bcl2, and the PI3K/AKT pathway, were involved in the SJZD treatment of GC. This evidence concerns the gene BCL2 and gastric cancer.